Advertisement
Table 2 Comparison of clinical and molecular characteristics of identified CRC subtypes
| iNMF step 1 | |||||
|---|---|---|---|---|---|
| Molecular feature | Type 1 | Type 2 | |||
| No. of tumor samples (AZTS) | 28 | 34 | |||
| No. of tumor samples (all datasets) | 944 | 762 | |||
| EMT expression signature | mesenchymal | epithelial | |||
| Survival prognosis | poor | good | |||
| Microsatellite status | similar number of MSI and MSS CRC | enriched with MSS CRC | |||
| iNMF step 2 | |||||
| Molecular feature | Subtype 1.1 | Subtype 1.2 | Subtype 1.3 | Subtype 2.1 | Subtype 2.2 |
| No. of tumor samples (AZTS) | 12 | 9 | 7 | 14 | 20 |
| No. of tumor samples (all datasets) | 313 | 303 | 328 | 313 | 449 |
| Average percent tumor foci area | 79.2 | 81.4 | 77.9 | 82.1 | 79.7 |
| Average percent tumor cells in foci | 76.3 | 74.5 | 80.0 | 73,8 | 73.7 |
| Average percent stromal cells in foci | 18.3 | 18.3 | 12.2 | 21.2 | 21.2 |
| Average percent inflammatory cells in foci | 3.8 | 7.2 | 6.4 | 3.5 | 4.7 |
| EMT expression signature | strongly mesenchymal | mesenchymal | mesenchymal | epithelial | epithelial |
| Tumor location colon/left/rectum/right | 0/26/16/15 | 1/12/1/29 | 0/12/2/11 | 1/22/9/37 | 1/50/11/33 |
| Microsatellite status MSI/MSS | 14/15 | 42/9 | 2/35 | 27/31 | 4/50 |
| Tumor stage | enriched in late stage CRC | ||||
| Gender enrichment Female/Male/Unknown | 87/99/0 | 89/57/0 | 90/124/1 | 58/34/0 | 108/113/0 |
| Up-regulated genes | Ca-signaling and SRF-targeted | immune system-related | transporters | stress response and immune system-related | cell cycle and amino acid synthesis; genes on 13q13, 13q14, 13q32-34 and 20q11and 20q13 |
